semaglutide risk of cancer Assessment Thyroid Carcinogenic and Safety Profile of GLP1-RA (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review Weight-loss drugs may lower cancer

Does Diet Coke Make You Retain Water

Semaglutide is a once-weekly injectable GLP-1 receptor agonist that mimics the natural hormone glucagon-like peptide-1, which controls appetite and blood sugar

Extreme emesis: cyclic vomiting syndrome

Palini S, Benedetti S, Tagliamonte MC, et al

Retatrutide is built on a backbone that combines structural elements from native GIP, GLP-1, and glucagon, three peptides that share a common evolutionary origin in the glucagon-secretin superfamily but have diverged significantly in their receptor recognition motifs

Patients taking insulin or sulfonylureas may need dose reductions of these medications to prevent hypoglycaemia as GLP-1 therapy improves glucose control